Stifel Financial Corp Sells 60,816 Shares of Genmab A/S (NASDAQ:GMAB)

Stifel Financial Corp lessened its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 36.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 108,175 shares of the company's stock after selling 60,816 shares during the quarter. Stifel Financial Corp's holdings in Genmab A/S were worth $2,258,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its stake in Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after buying an additional 939 shares during the last quarter. Lindbrook Capital LLC raised its position in shares of Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after purchasing an additional 950 shares during the last quarter. GAMMA Investing LLC grew its position in Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after purchasing an additional 1,051 shares during the last quarter. Barclays PLC increased its stake in Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after purchasing an additional 2,285 shares in the last quarter. Finally, Cromwell Holdings LLC lifted its stake in shares of Genmab A/S by 656.8% in the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after buying an additional 2,496 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Stock Down 5.7 %

Genmab A/S stock traded down $1.18 during midday trading on Thursday, reaching $19.42. 3,192,238 shares of the stock traded hands, compared to its average volume of 1,077,055. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $30.41. The stock's fifty day moving average is $20.22 and its 200-day moving average is $20.93. The stock has a market cap of $12.45 billion, a P/E ratio of 11.16, a PEG ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.26 by $0.05. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, equities analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on GMAB. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a report on Thursday, February 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $37.00 price objective (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $39.17.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.